` GNFT (Genfit SA) vs DAX Index Comparison - Alpha Spread

G
GNFT
vs
D
DAX Index

Over the past 12 months, GNFT has significantly outperformed DAX Index, delivering a return of +48% compared to the DAX Index's +19% growth.

Stocks Performance
GNFT vs DAX Index

Loading
GNFT
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
GNFT vs DAX Index

Performance Gap Between GNFT and GDAXI
HIDDEN
Show

Performance By Year
GNFT vs DAX Index

Loading
GNFT
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Genfit SA vs Peers

DAX Index
GNFT
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Genfit SA
Glance View

Market Cap
260m EUR
Industry
Biotechnology

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

GNFT Intrinsic Value
HIDDEN
Show
Back to Top